Exane Derivatives’s Bristol-Myers Squibb BMY Stock Holding History

Exane Derivatives’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1.32M	Buy	17,094 +6,261	+58%	+$477K	0.76%	30
2022 Q1	$791K	Sell	10,833 -11,351	-51%	-$762K	0.22%	122
2021 Q4	$1.38M	Buy	22,184 +4,175	+23%	+$245K	0.33%	61
2021 Q3	$1.07M	Buy	18,009 +470	+3%	+$31K	0.26%	81
2021 Q2	$1.18M	Sell	17,539 -1,165	-6%	-$76K	0.27%	85
2021 Q1	$1.18M	Sell	18,704 -307	-2%	-$19.1K	0.34%	67
2020 Q4	$1.18M	Sell	19,011 -17,572	-48%	-$1.08M	0.35%	63
2020 Q3	$2.21M	Buy	36,583 +18,001	+97%	+$1.08M	0.64%	36
2020 Q2	$1.09M	Sell	18,582 -2,968	-14%	-$178K	0.29%	85
2020 Q1	$1.2M	Sell	21,550 -826	-4%	-$50.5K	0.34%	72
2019 Q4	$1.49M	Buy	22,376 +6,485	+41%	+$371K	0.28%	93
2019 Q3	$806K	Buy	15,891 +10,200	+179%	+$479K	0.14%	118
2019 Q2	$258K	Sell	5,691 -8,429	-60%	-$393K	0.05%	233
2019 Q1	$673K	Sell	14,120 -13,061	-48%	-$651K	0.13%	138
2018 Q4	$1.41M	Buy	27,181 +22,454	+475%	+$1.21M	0.25%	92
2018 Q3	$293K	Sell	4,727 -6,517	-58%	-$387K	0.06%	207
2018 Q2	$626K	Buy	11,244 +6,320	+128%	+$341K	0.1%	159
2018 Q1	$309K	Buy	4,924 +266	+6%	+$17.1K	0.06%	193
2017 Q4	$286K	Buy	4,658 +1,055	+29%	+$66K	0.05%	206
2017 Q3	$230K	Sell	3,603 -2,013	-36%	-$118K	0.04%	192
2017 Q2	$313K	Sell	5,616 -1,568	-22%	-$85.3K	0.07%	171
2017 Q1	$391K	Buy	7,184 +5,414	+306%	+$297K	0.09%	147
2016 Q4	$103K	Sell	1,770 -14,361	-89%	-$785K	0.02%	247
2016 Q3	$870K	Buy	16,131 +13,491	+511%	+$867K	0.13%	101
2016 Q2	$194K	Sell	2,640 -2,505	-49%	-$177K	0.03%	202
2016 Q1	$329K	Buy	5,145 +836	+19%	+$52.7K	0.04%	165
2015 Q4	$296K	Buy	4,309 +1,831	+74%	+$121K	0.04%	142
2015 Q3	$147K	Buy	2,478 +1,388	+127%	+$88.1K	0.02%	204
2015 Q2	$72.5K	Hold	1,090	–	–	0.01%	268
2015 Q1	$70.3K	Sell	1,090 -1,606	-60%	-$101K	0.01%	290
2014 Q4	$159K	Buy	+2,696	New	+$152K	0.02%	241

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Exane Derivatives's BMY Position: Q2 2022 in Review

Exane Derivatives increased its Bristol-Myers Squibb (BMY) stake by 58% in Q2 2022, buying an estimated $477K and bringing the position to 17,094 shares worth $1.32M. The position accounts for 0.76% of the portfolio, ranked #30.

Exane Derivatives first reported a position in BMY in Q4 2014 and has held it in 31 quarters since. The position peaked at $2.21M in Q3 2020. 2,538 funds tracked by Wall St. Rank hold BMY as of Q2 2022.

Exane Derivatives held 17,094 shares of Bristol-Myers Squibb worth $1.32M as of Q2 2022.
Exane Derivatives bought 6,261 Bristol-Myers Squibb shares in Q2 2022, an estimated $477K.
Bristol-Myers Squibb made up 0.76% of Exane Derivatives's portfolio in Q2 2022, its #30 holding.
Exane Derivatives first reported a position in Bristol-Myers Squibb in Q4 2014 and has held it in 31 quarters since.
Exane Derivatives's Bristol-Myers Squibb position peaked at $2.21M in Q3 2020.
2,538 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.